Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2026-06-08 Declaration of Voting R…
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K (Current Report) under Item 5.07 “Submission of Matters to a Vote of Security Holders,” reporting vote tallies for director elections, appointment of auditors, and advisory compensation vote at the 2026 Annual Meeting. This is a Declaration of Voting Results. Therefore, the correct classification is DVA.
2026-06-08 English
10-Q
Interim / Quarterly Report
2026-05-14 English
8-K
Regulatory Filings Classification · 90% confidence The document is a Form 8-K filed with the SEC reporting ‘Results of Operations and Financial Condition’ under Item 2.02 and includes an attached press release for quarterly results. This is a regulatory compliance filing rather than the report itself, fitting the "Regulatory Filings (RNS)" category.
2026-05-14 English
ARS - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
Annual Report
2026-04-22 English
424B3 - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to rule 424(b)(3) related to a common stock offering of up to $100 million. It describes the terms of the offering, the sales agreement with TD Cowen, risk factors, use of proceeds, and other offering details. It references a shelf registration statement and incorporates by reference the company's Annual Report on Form 10-K and other SEC filings. The document is a detailed disclosure related to capital raising and securities offering, not a financial report, earnings release, or management discussion. It is clearly a capital/financing update describing a securities offering and related terms. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2026-04-01 English
S-3 - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the offering of securities by Sutro Biopharma, Inc. The text includes details about the securities to be offered, the registration process, and disclaimers about the prospectus. This type of filing is related to capital raising and financing activities, specifically the registration of securities for sale to the public. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not just an announcement or a brief notice, so it is not RPA or RNS.
2026-03-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.